Docoh
Loading...

TCON TRACON Pharmaceuticals

News

Pro users get this 30m faster
TRACON Pharma, Eucure Join Forces To Develop CTLA-4 Antibody For Oncology Indications
11 Oct 21
Biotech, News, Penny Stocks, Health Care, Contracts, Movers, Trading Ideas, General
12 Health Care Stocks Moving In Monday's Pre-Market Session
11 Oct 21
Pre-Market Outlook, Markets, Movers
Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares moved upwards by 89.3% to $34.53 during Monday's pre-market session. The market value of their outstanding shares is at $1.6 billion.
TRACON Pharmaceuticals And Eucure Biopharma Announce Partnership For Development Of Clinical Stage CTLA-4 Antibody YH001
11 Oct 21
News, Contracts, FDA
TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent
TRACON Pharmaceuticals on the Fast Track for Sarcoma Injection Treatments
7 Sep 21
Biotech, Penny Stocks, Health Care, General
Sarcoma is not one of the many cancers that reaches top billing in the discussion of cancer research.
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Earnings Scheduled For August 11, 2021
11 Aug 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second quarter.
TRACON Pharmaceuticals Announces Independent Data Monitoring Committee For ENVASARC Pivotal Trial Has Recommended Trial Proceed As Planned
9 Aug 21
Biotech, General
TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent
3 Penny Stocks Insiders Are Buying
28 Jul 21
News, Penny Stocks, Insider Trades, Intraday Update, Markets
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
12 Health Care Stocks Moving In Monday's After-Market Session
26 Jul 21
Movers
Gainers Eyegate Pharmaceuticals (NASDAQ:EYEG) stock increased by 25.64% to $3.92 during Monday's after-market session. The company's market cap stands at $27.8 million.
61 Biggest Movers From Yesterday
23 Jul 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
Mid-Afternoon Market Update: Dow Rises Over 50 Points; ImmunoPrecise Antibodies Shares Spike Higher
22 Jul 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Toward the end of trading Thursday, the Dow traded up 0.16% to 34,853.89 while the NASDAQ rose 0.38% to 14,687.85. The S&P also rose, gaining 0.20% to 4,367.55.
38 Stocks Moving In Thursday's Mid-Day Session
22 Jul 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) shares climbed 129.7% to $12.75 after the company announced new results from its TATX-03 PolyTope Therapy, demonstrating potent pseudovirus neutralizing activity against the SARS-CoV-2 Delta (B.1.617.2) variant.
Mid-Day Market Update: Crude Oil Up 1.5%; Seres Therapeutics Shares Plunge
22 Jul 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Midway through trading Thursday, the Dow traded down 0.08% to 34,768.64 while the NASDAQ rose 0.10% to 14,646.39. The S&P also fell, dropping 0.02% to 4,357.70.
12 Health Care Stocks Moving In Thursday's Intraday Session
22 Jul 21
Intraday Update, Markets, Movers
Mid-Morning Market Update: Markets Mostly Lower; AT&T Beats Q2 Estimates
22 Jul 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Following the market opening Thursday, the Dow traded down 0.24% to 34,715.42 while the NASDAQ rose 0.13% to 14,651.19. The S&P also fell, dropping 0.08% to 4,355.29.
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, Absci IPO
22 Jul 21
Biotech, Earnings, News, Penny Stocks, Dividends, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21)
21 Stocks Moving in Thursday's Pre-Market Session
22 Jul 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers PainReform Ltd (NASDAQ: PRFX) shares rose 123% to $7.00 in pre-market trading.
TRACON Pharmaceuticals Increased Previously Announced Bought Deal Offering of Common Stock to $15M
22 Jul 21
News, Penny Stocks, Offerings
TRACON Pharmaceuticals (NASDAQ: TCON) ("TRACON" or the "Company"), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering a
12 Health Care Stocks Moving In Wednesday's After-Market Session
21 Jul 21
Movers
Gainers
TRACON Pharmaceuticals Announces $10M Bought Deal Offering Of Common Stock
21 Jul 21
News, Offerings
TRACON Pharmaceuticals (NASDAQ:TCON) ("TRACON" or the "Company"), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer

Press releases

Pro users get this 30m faster
TRACON Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
13 Sep 21
News, Press Releases
SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and
TRACON Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
7 Sep 21
News, Health Care, Press Releases
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and
TRACON Pharmaceuticals to Present at the Wells Fargo Virtual Healthcare Conference
2 Sep 21
News, Press Releases
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and
Capital Efficient: Clinical Stage NASDAQ Company – Novel Targeted Cancer Therapeutics Company: TRACON Pharmaceuticals (NASDAQ: TCON)
16 Aug 21
News, Press Releases
Clinical Trials Progressing on Multiple Novel Cancer Treatments. Capital Efficient, CRO Independent Product Development Platform. $25.6 Million Cash + $15 Million From Recent Offering Extends Cash Runway
TRACON Pharmaceuticals Announces Results of Second Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial
9 Aug 21
Analyst Ratings, Press Releases
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and
TRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
3 Aug 21
News, Press Releases
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and
TRACON to Report Second Quarter 2021 Financial Results and Company Highlights on August 11, 2021
28 Jul 21
News, Press Releases
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and
TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million
21 Jul 21
Markets, Press Releases
SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON) ("TRACON" or the "Company"), a clinical stage biopharmaceutical company focused on the development and commercialization of novel
TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock
21 Jul 21
News, Financing, Press Releases
SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON) ("TRACON" or the "Company"), a clinical stage biopharmaceutical company focused on the development and commercialization of novel